{"id":"NCT03620747","sponsor":"Sanofi","briefTitle":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","officialTitle":"Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-30","primaryCompletion":"2022-02-18","completion":"2022-02-18","firstPosted":"2018-08-08","resultsPosted":"2023-03-16","lastUpdate":"2023-03-16"},"enrollment":393,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Dupilumab SAR231893 (REGN668)","otherNames":[]}],"arms":[{"label":"Dupilumab","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).","primaryOutcome":{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From first dose of IMP up to 12 weeks after last dose of IMP (maximum duration: up to 144 Weeks)","effectByArm":[{"arm":"Dupilumab","deltaMin":54.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":132,"countries":["United States","Argentina","Belgium","Canada","France","Germany","Israel","Japan","Netherlands","South Africa"]},"refs":{"pmids":["38163585"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":393},"commonTop":["Asthma","Nasopharyngitis","COVID-19"]}}